96 related articles for article (PubMed ID: 11313191)
1. New developments in interferon therapy.
Tossing G
Eur J Med Res; 2001 Feb; 6(2):47-65. PubMed ID: 11313191
[TBL] [Abstract][Full Text] [Related]
2. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons.
Pfeffer LM; Dinarello CA; Herberman RB; Williams BR; Borden EC; Bordens R; Walter MR; Nagabhushan TL; Trotta PP; Pestka S
Cancer Res; 1998 Jun; 58(12):2489-99. PubMed ID: 9635566
[TBL] [Abstract][Full Text] [Related]
3. Human renal cancers resistant to IFN's antiproliferative action exhibit sensitivity to IFN's gene-inducing and antiviral actions.
Pfeffer LM; Wang C; Constantinescu SN; Croze E; Blatt LM; Albino AP; Nanus DM
J Urol; 1996 Nov; 156(5):1867-71. PubMed ID: 8863634
[TBL] [Abstract][Full Text] [Related]
4. Second-generation interferons for cancer: clinical targets.
Borden EC; Lindner D; Dreicer R; Hussein M; Peereboom D
Semin Cancer Biol; 2000 Apr; 10(2):125-44. PubMed ID: 10936063
[TBL] [Abstract][Full Text] [Related]
5. Biological standardization of human interferon beta: establishment of a replacement world health organization international biological standard for human glycosylated interferon beta.
Meager A; Das RG
J Immunol Methods; 2005 Nov; 306(1-2):1-15. PubMed ID: 16226271
[TBL] [Abstract][Full Text] [Related]
6. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
7. [New aspects of interferon therapy in malignant diseases].
Micksche M
Wien Med Wochenschr; 1993; 143(16-17):454-7. PubMed ID: 7505990
[TBL] [Abstract][Full Text] [Related]
8. Biological basis for a proper clinical application of alpha interferons.
Antonelli G
New Microbiol; 2008 Jul; 31(3):305-18. PubMed ID: 18843884
[TBL] [Abstract][Full Text] [Related]
9. Stat1-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand and the cell-surface death signaling pathway by interferon beta in human cancer cells.
Choi EA; Lei H; Maron DJ; Wilson JM; Barsoum J; Fraker DL; El-Deiry WS; Spitz FR
Cancer Res; 2003 Sep; 63(17):5299-307. PubMed ID: 14500361
[TBL] [Abstract][Full Text] [Related]
10. [The interferon system. A review of biological principles and clinical uses].
Schneider FJ
Z Gesamte Inn Med; 1986 Nov; 41(22):613-8. PubMed ID: 2436387
[TBL] [Abstract][Full Text] [Related]
11. Interferon-based therapy of hepatitis C.
Chevaliez S; Pawlotsky JM
Adv Drug Deliv Rev; 2007 Oct; 59(12):1222-41. PubMed ID: 17869375
[TBL] [Abstract][Full Text] [Related]
12. Interferon-alpha as an immunotherapeutic protein.
Brassard DL; Grace MJ; Bordens RW
J Leukoc Biol; 2002 Apr; 71(4):565-81. PubMed ID: 11927642
[TBL] [Abstract][Full Text] [Related]
13. Directed evolution of gene-shuffled IFN-alpha molecules with activity profiles tailored for treatment of chronic viral diseases.
Brideau-Andersen AD; Huang X; Sun SC; Chen TT; Stark D; Sas IJ; Zadik L; Dawes GN; Guptill DR; McCord R; Govindarajan S; Roy A; Yang S; Gao J; Chen YH; Skartved NJ; Pedersen AK; Lin D; Locher CP; Rebbapragada I; Jensen AD; Bass SH; Nissen TL; Viswanathan S; Foster GR; Symons JA; Patten PA
Proc Natl Acad Sci U S A; 2007 May; 104(20):8269-74. PubMed ID: 17494769
[TBL] [Abstract][Full Text] [Related]
14. [Human interferons: biological and clinical promises and premises].
Jasmin C
Schweiz Med Wochenschr; 1991 Mar; 121(13):463-6. PubMed ID: 1709521
[TBL] [Abstract][Full Text] [Related]
15. Use of oromucosally administered interferon-alpha in the prevention and treatment of animal diseases.
Dec M; Puchalski A
Pol J Vet Sci; 2008; 11(2):175-86. PubMed ID: 18683548
[TBL] [Abstract][Full Text] [Related]
16. Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells.
Papageorgiou A; Lashinger L; Millikan R; Grossman HB; Benedict W; Dinney CP; McConkey DJ
Cancer Res; 2004 Dec; 64(24):8973-9. PubMed ID: 15604261
[TBL] [Abstract][Full Text] [Related]
17. Molecular biological assessment methods and understanding the course of the HIV infection.
Katzenstein TL
APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
[TBL] [Abstract][Full Text] [Related]
18. Significance of anti-interferon-alpha2 and sICAM-1 activities in the sera of viral hepatitis B and C patients treated with human recombinant interferon-alpha2.
Stancek D; Fuchsberger N; Oltman M; Schmeisser H; Kontsek P; Jahnová E; Hajnická V
Acta Virol; 2001; 45(5-6):287-92. PubMed ID: 12083327
[TBL] [Abstract][Full Text] [Related]
19. Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency.
Dupuis S; Jouanguy E; Al-Hajjar S; Fieschi C; Al-Mohsen IZ; Al-Jumaah S; Yang K; Chapgier A; Eidenschenk C; Eid P; Al Ghonaium A; Tufenkeji H; Frayha H; Al-Gazlan S; Al-Rayes H; Schreiber RD; Gresser I; Casanova JL
Nat Genet; 2003 Mar; 33(3):388-91. PubMed ID: 12590259
[TBL] [Abstract][Full Text] [Related]
20. Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).
Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R
Clin Ter; 2006; 157(4):377-86. PubMed ID: 17051976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
